Market Overview

Morgan Stanley Sees Attractive Entry Point for Abbott Laboratories

Share:
Related ABT
Top Performing Industries For June 16, 2015
Mylan Offers Response to Abbott's Support for Perrigo Deal
BG Med's largest customer bankrupt but galectin-3 purchases continue (for now) (Seeking Alpha)

In a report published Thursday, Morgan Stanley analyst David R. Lewis reiterated an Overweight rating and $45.00 price target on Abbott Laboratories (NYSE: ABT).

In the report, Morgan Stanley noted, “The most challenging quarter of the year is behind the company and we see clarity to acceleration ahead. Consensus under-appreciates margin momentum into 2H14 and 15'. As EPS and revenue move higher into 2Q, shares will follow. Reiterate our OW thesis and $45 target.”

Abbott Laboratories closed on Wednesday at $38.38.

Latest Ratings for ABT

DateFirmActionFromTo
Jun 2015BTIG ResearchInitiates Coverage onBuy
May 2015Evercore PartnersInitiates Coverage onBuy
May 2015Evercore ISIInitiates Coverage onBuy

View More Analyst Ratings for ABT
View the Latest Analyst Ratings

Posted-In: David R. Lewis Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (ABT)

Around the Web, We're Loving...

Get Benzinga's Newsletters